Latest Commercialization News

Neurizon Therapeutics has secured trademark protection for its NEURIZON® brand across major pharmaceutical markets, reinforcing its intellectual property strategy as it advances its lead drug candidate NUZ-001.

FBR Limited has secured a binding conditional purchase order worth AUD 990,000 from a leading US heavy equipment dealer for its Mantis welding robot, marking a significant milestone during its prototyping phase.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

Australian Rare Earths has demonstrated a low-risk, scalable process producing a high-purity mixed rare earth oxide with 99.9% recovery, positioning its Koppamurra project as a strategic supplier amid tightening global rare earth markets.

Origin Energy has announced it will keep the Eraring Power Station operational until April 2029, extending its life by nearly two years to bolster NSW’s energy security during the shift to renewables.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Golden State Mining Limited has appointed a new board and managing director, completed a $1.5 million capital raising, and is advancing exploration with a disciplined approach focused on its Western Australian gold projects.

Pioneer Minerals has validated primary tungsten mineralisation at its Springfield Prospect in Idaho, revealing high-grade scheelite and gold assays that underpin a promising multi-phase mineral system. The project’s proximity to established processing infrastructure offers strategic advantages for future development.

Pacific Edge reports a 13.4% decline in test volumes for Q3 2026 but gains strategic momentum with a key Medicare advisory meeting and clinical endorsements poised to influence reimbursement policy.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Trek Metals reports exceptional high-grade manganese rock chip assays up to 60.1% Mn at its Kuro Prospect, extending mineralisation over 750 metres and aligning with strong gravity anomalies. Drill preparations and heritage assessments are underway to unlock the discovery’s full potential.